Morphological substrates of dementia in parkinsonism A critical update

  • K. A. Jellinger
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 51)


Dementia in parkinsonism is caused by a variety of central nervous system (CNS) lesions, of which the molecular and pathogenic causes are poorly understood but probably include: 1. Degeneration of subcortical ascending systems with neuronal losses in dopaminergic, noradrenergic, serotonergic, cholinergic or multiple systems including the amygdyloid nucleus; 2. limbic and/or cortical Alzheimer and/or Lewy body pathologies, with loss of synapses and neurons, and 3. a combination of these lesions or additional CNS pathologies. In general, degeneration of subcortical neuronal networks appears insufficient to induce severe mental decline although, occasionally, cognitive impairment occurs without apparent cortical lesions. On the other hand, neuritic cortical Alzheimer change showing similar or differential distribution compared to Alzheimer’s disease (AD) displays a significant linear correlation with dementia in Parkinsonism. Plaques can be associated with cortical Lewy bodies and, the contribution of each to dementing processes remains unresolved. In a consecutive autopsy series of 610 patients with parkinsonism, the total prevalence of retrospectively assessed dementia was 34.6%. In Parkinson’s disease (PD) of the Lewy body type, it was 30.2%, mostly associated with other brain lesions, mainly AD, while only 3.5% of “pure” PD without additional brain pathologies were demented. There was no significant difference in age and duration of illness between demented and non-demented PD patients. Secondary parkinsonian syndromes showed a higher incidence of dementia (56.3%), again with predominant Alzheimer pathology which was present in 73% of the total of demented parkinsonian patients and in almost 82% of the demented PD cases in this series. The specific contribution of cortical and subcortical lesions to mental impairment in parkinsonism, their relationship to AD, and an etiology await further elucidation.


Alzheimer Disease Multiple System Atrophy Progressive Supranuclear Palsy Lewy Body Dementia Substantia Nigra Zona Compacta 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Agid Y, Graybiel AM, Ruberg M, Hirsch E, Blin J, Dubois B, Javoy-Agid F (1990) The efficacy of levodopa treatment declines in the course of Parkinson’s disease. Do non-dopaminergic lesions play a role? Adv Neurol 53: 83–100.PubMedGoogle Scholar
  2. Albin RL (1995) The pathophysiology of chorea/ballism and parkinsonism. Parkinsonism Rel Disord 1: 3–11.CrossRefGoogle Scholar
  3. Allard PO, Rinner J, Marcusson JO (1995) Dopamine uptake sites in Parkinson’s disease and in dementia of the Alzheimer type. Brain Res 637: 262–266.CrossRefGoogle Scholar
  4. Amaral DG, Price JL, Pitkänen A, Carmichael ST (1992) Anatomical organization of the primate amygdaloid complex. In: Aggleton JP (ed) The amygdala: neurobiological aspects of emotion, memory, and mental dysfunction. Wiley-Liss, New York, pp 1–66.Google Scholar
  5. Arai H, Schmidt ML, Lee VM-Y, Hurtig HI, Greenberg BD, Adler CH, Trojanowski JQ (1992) Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson’s disease. Neurology 42: 1315–1322.PubMedCrossRefGoogle Scholar
  6. Arriagada PV, Marzloff K, Hyman BT (1992) Distribution of Alzheimer-type pathologic changes in non-demented elderly individuals matches the pattern in Alzheimer’s disease. Neurology 42: 1681–1688.PubMedCrossRefGoogle Scholar
  7. Bancher C, Braak H, Fischer P, Jellinger K (1993) Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer’s and Parkinson’s disease. Neurosci Lett 162: 179–182.PubMedCrossRefGoogle Scholar
  8. Bancher C, Jellinger K, Lassmann H, et al. (1996) Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci 246: 137–146.PubMedCrossRefGoogle Scholar
  9. Berlit P (1987) Neurologischer Diagnoseschlüssel der internationalen Klassifikation der Krankheiten der WHO (ICD-NA). Springer, Berlin Heidelberg New York Tokyo.CrossRefGoogle Scholar
  10. Bierer LM, Hof PR, Purohit DP, Carlin L, Schmeidler J, Davis KL, Perl DP (1995) Neocortical neurofibrillary tangles correlate with dementia severity in Alzheimer’s disease. Arch Neurol 52: 81–88.PubMedCrossRefGoogle Scholar
  11. Biggins CA, Boyd JL, Harrop FM, Madeley P, Mindham RHS, Randall JI, Spokes EGS (1992) A controlled, longitudinal study of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 55: 566–571.PubMedCrossRefGoogle Scholar
  12. Boller F, Mizutani T, Roessmann U, Gambetti P (1980) Parkinson’s disease, dementia, and Alzheimer’s disease. Clinico-pathological correlations. Ann Neurol 7: 329–335. PubMedCrossRefGoogle Scholar
  13. Bouras C, Hof PR, Morrison JH (1993) Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes. Neurosci Lett 153: 131–135.PubMedCrossRefGoogle Scholar
  14. Braak H, Braak E (1990) Cognitive impairment in Parkinson’s disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex. J Neural Transm [P-D Sect] 2: 45–57.CrossRefGoogle Scholar
  15. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239–259.PubMedCrossRefGoogle Scholar
  16. Braak H, Braak E (1992) The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res 15: 6–31.PubMedCrossRefGoogle Scholar
  17. Braak H, Braak E (1994) Pathology of Alzheimer’s disease. In: Calne DB (ed) Neurodegenerative disease. Saunders, Philadelphia, pp 585–613.Google Scholar
  18. Braak H, Jellinger K, Braak E, Bohl J (1992) Allocortical neurofibrillary changes in progressive supranuclear palsy. Acta Neuropathol 64: 478–483.CrossRefGoogle Scholar
  19. Braak H, Duyckaerts C, Braak E, Piette F (1993) Neuropathological staging of Alzheimer-related changes correlates with psychometrically assessed intellectual status. In: Corain B, et al. (eds) Alzheimer’s disease. Advances in clinical and basic research. John Wiley, New York, pp 131–137.Google Scholar
  20. Braak H, Braak E, Yilmazer D, De Ros RAI, Jansen ENH, Bohl J, Jellinger K (1994) Amygdala pathology in Parkinson’s disease. Acta Neuropathol 88: 493–500.PubMedCrossRefGoogle Scholar
  21. Braak H, Braak E, Mandelkow EM (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87: 554–567.PubMedCrossRefGoogle Scholar
  22. Brooks DJ (1993) Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 115: 1–17.PubMedCrossRefGoogle Scholar
  23. Buée-Scherrer V, Buée L, Hof PR, Leveugle-Giolles C, Loerzel AJ, Perl DP, Delacourte A (1995) Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism dementia complex of Guam: immunochemical characterization of tau proteins. Am J Pathol 68: 924–932.Google Scholar
  24. Caporro-Lefevre D, Pecheus N, Petit Y, Duhamel A, Petit H (1995) Which factors predict cognitive decline in Parkinson’s disease? J Neurol Neurosurg Psychiatry 58: 51–55.CrossRefGoogle Scholar
  25. Chan-Palay V (1993) Depression and dementia in Parkinson’s disease: catecholaminergic changes in the locus ceruleus. A basis for therapy. Adv Neurol 60: 438–446.Google Scholar
  26. Chan-Palay V, Hochli M, Jentsch B, Leonard B, Zetzsche T (1992) Raphe serotonin neurons in the human brain in normal controls and patients with senile dementia of the Alzheimer type and Parkinson’s disease. Dementia 3: 253–269.Google Scholar
  27. Chui HC, Mortimer JA, Slager U (1986) Pathologic correlates of dementia in Parkinson’s disease. Arch Neurol 43: 991–995.PubMedCrossRefGoogle Scholar
  28. Curren T, Lang AE (1994) Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses. Mov Disord 9:508–520.CrossRefGoogle Scholar
  29. Daniel SE, Lees AJ (1991) Neuropathological features of Alzheimer’s disease in non-demented parkinsonian patients. J Neurol Neurosurg Psychiatry 54: 972–975.PubMedCrossRefGoogle Scholar
  30. Dickson DW, Schmidt ML, Lee VMY, Zhao ML, Yen SH, Trojanowski JQ (1994) Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol 87: 269–276.PubMedCrossRefGoogle Scholar
  31. DSM-III-R (1987) Diagnostic and statistical manual of mental disorders, 3rd edn, revised. American Psychiatric Association, Washington.Google Scholar
  32. Dubois B, Boller F, Pillon B, Agid Y (1991) Cognitive deficits in Parkinson’s disease. In: Boller F, Grafman J (eds) Handbook of neuropsychology, vol 5. Elsevier, Amsterdam, pp 195–240.Google Scholar
  33. Dubois B, Malapani C, Verin M, Rogelet P, Deweer B, Pillon B (1994) Cognitive functions and the basal ganglia. The model of Parkinson’s disease. Rev Neurol 150: 763–770.Google Scholar
  34. Duyckaerts C, Gaspar P, Costa C, Bonnet M, Hauw JJ (1993) Dementia in Parkinson’s disease. Morphometric data. Adv Neurol 60: 447–455.Google Scholar
  35. Fearnley J, Lees A (1994) Pathology of Parkinson’s disease. In: Calne DB (ed) Neurodegenerative diseases. Saunders, Philadelphia, pp 545–554.Google Scholar
  36. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-Mental Stat”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12: 189–198.CrossRefGoogle Scholar
  37. Friedman A, Barczikowska M (1994) Dementia in Parkinson’s disease. Dementia 5: 12–16.PubMedGoogle Scholar
  38. Gai WP, Blessing WW, Blumbergs PC (1995) Ubiquitin-positive degenerating neurites in the brainstem in Parkinson’s disease. Brain 118: 1447–1459.PubMedCrossRefGoogle Scholar
  39. Gaspar P, Gray F (1984) Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases. Acta Neuropathol 64: 43–52.PubMedCrossRefGoogle Scholar
  40. Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Boger B (1991) Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease. Ann Neurol 30: 365–374.PubMedCrossRefGoogle Scholar
  41. Gerlach M, Riederer P (1993) The pathophysiological basis of Parkinson’s disease. In: Szeleny I (ed) Inhibitors of monoamine oxidase B. Pharmacology and clinical use in neurodegenerative disorders. Birkhäuser, Basle, pp 25–50.Google Scholar
  42. Gerlach M, Jellinger K, Riederer P (1994) The possible role of noradrenergic deficits in selected signs of Parkinson’s disease. In: Briley M, Marien M (eds) Noradrenergic mechanisms in Parkinson’s disease. CRC Press, Boca Raton, pp 59–71.Google Scholar
  43. German DC, Manaye KF, White CL (1992) Disease specific patterns of locus ceruleus cell loss. Ann Neurol 32: 667–676.PubMedCrossRefGoogle Scholar
  44. Groenewegen JH, Roeling T, Voorn P, Berendse H (1993) The parallel arrangement of basal ganglia-thalamocortical circuits: a neuronal substrate for the role of dopamine in motor and cognitive functions? In: Wolters EC, Scheltens P (eds) Mental dysfunction in Parkinson’s disease. Vrije Universiteit, Amsterdam, pp 3–18.Google Scholar
  45. Halliday GM, McCann HL, Pamphlett R, et al. (1992) Brain stem serotonin-synthesizing neurons in Alzheimer’s disease: a clinico-pathologic correlation. Acta Neuropathol 84: 638–650.PubMedCrossRefGoogle Scholar
  46. Hansen LA, Masliah E, Quidjada-Fawcett S, Rexin D (1991) Entorhinal neurofibrillary tangles in Alzheimer’s disease with Lewy bodies. Neurosci Lett 129: 269–272.PubMedCrossRefGoogle Scholar
  47. Hansen LA, Masliah E, Galasko D, Terry RD (1993) Plaque-only Alzheimer disease is usually the Lewy body variant and vice versa. J Neuropathol Exp Neurol 52: 648–654.PubMedCrossRefGoogle Scholar
  48. Hardy J, Crook R, Prihar G, Roberts G, Raghavan R, Perry R (1994) Senile dementia of the Lewy body type has an apolipoprotein E epsilon 4 allele frequency intermediate between controls and Alzheimer’s disease. Neurosci Lett 182: 1–2.PubMedCrossRefGoogle Scholar
  49. Harrington CR, Perry RH, Perry EK, Hurt J, McKeith IG, Roth M, Wischik CM (1994a) Senile dementia of Lewy body type and Alzheimer type are biochemically distinct in terms of paired helical filaments and hyperphosphorylated tau protein. Dementia 5: 215–228.PubMedGoogle Scholar
  50. Harrington CR, Louwagie J, Rossau R, Vanmechelen E, Perry RH, Perry EK, Xuereb JH, Roth M, Wischik CM (1994b) Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Am J Pathol 145: 1472–1484.PubMedGoogle Scholar
  51. Hedera P, Lerner AJ, Castellani R, Friedland RP (1995) Concurrence of Alzheimer’s disease, Parkinson’s disease, diffuse Lewy body disease, and amyotrophic lateral sclerosis. J Neurol Sci 128: 219–224.PubMedCrossRefGoogle Scholar
  52. Heinonen O, Soininen H, Sorvari H, Kosunen O, Paljärvi I, Koivisto E, Riekkienen PJ (1995) Loss of synaptophysin-like immunoreactivity in the hippocampal formation as an early phenomenon in Alzheimer’s disease. Neuroscience 64: 375–384.PubMedCrossRefGoogle Scholar
  53. Hoehn MM, Yahr M (1967) Parkinsonism. Onset, progression, and mortality. Neurology 17: 427–442.PubMedCrossRefGoogle Scholar
  54. Hof PR, Morrison JH (1994) The cellular basis of cortical disconnection in Alzheimer disease and related dementing conditions. In: Terry RD, Katzmann R, Bick KL (eds) Alzheimer disease. Raven Press, New York, pp 197–229.Google Scholar
  55. Hof PR, Nimchinsky EA, Buée-Scherrer V, Buée L, Nasrallah J, Hottinger AF, Purohit DP, Loerzel AJ, Steele JC, Delacourte A, Bouras C, Morrison JH, Perl DP (1994) Amyotrophic lateral sclerosis/parkinsonism-demetia complex of Guam: quantitative neuropathology, immunohistochemical analysis of neuronal vulnerability, and comparison with related neurodegenerative disorders. Acta Neuropathol 88: 397–404.PubMedCrossRefGoogle Scholar
  56. Hoogendijk WJG, Pall CW, Troost D, Venzweiten E, Swaab DF (1995) Image analysis-assisted morphometry of the locus ceruleus in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Brain 118: 131–143.PubMedCrossRefGoogle Scholar
  57. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease. A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181–184.PubMedCrossRefGoogle Scholar
  58. Hyman BT, Van Hoesen GW, Kromer LJ, Damasio AR (1986) Perforant pathway changes and the memory impairment in Alzheimer disease. Ann Neurol 20: 37–40.CrossRefGoogle Scholar
  59. Ince PG, McArthur FK, Bjertness E, Torvik A, Condy JM, Edwardson JA (1995) Neuropathological diagnosis in elderly patients in Oslo — Alzheimer’s disease, Lewy body disease, vascular lesions. Dementia 6: 162–166.PubMedGoogle Scholar
  60. Insausti R, Tunon T, Sobreviela T, Insausti AM, Gonzalo LM (1995) The human entorhinal cortex. A cytoarchitectonic analysis. J Comp Neurol 355: 171–198.CrossRefGoogle Scholar
  61. Javoy-Agid F, Scatton B, Ruberg M, L’Heureux L, Cervera P, Raisman R, Maloteaus JM, Beck H, Agid Y (1989) Distribution of monoaminergic, cholinergic and gabaergic markers in the human cerebral cortex. Neuroscience 29: 251–269.PubMedCrossRefGoogle Scholar
  62. Jellinger K (1987) Neuropathological substrates of Alzheimer’s and Parkinson’s disease. J Neural Transm [Suppl] 24: 109–129.Google Scholar
  63. Jellinger K (1990) New developments in the pathology of Parkinson’s disease. Adv Neurol 53: 1–16.PubMedGoogle Scholar
  64. Jellinger K (1991) Pathology of Parkinson’s disease: changes other than the nigro-striatal pathway. Mol Chem Neuropathol 14: 153–198.PubMedCrossRefGoogle Scholar
  65. Jellinger K (1994) Structural basis of dementia in Parkinson’s disease. In: Korczyn AD (ed) Dementia in Parkinson’s disease. Monduzzi Ed, Bologna, pp 31–38.Google Scholar
  66. Jellinger KA, Bancher C (1995) Structural basis of mental impairment in Parkinson’s disease. Neuropsychiatrie 9: 9–14.Google Scholar
  67. Jellinger KA, Bancher C (1996) Dementia with Lewy bodies. Relationship to Parkinson’s and Alzheimer’s disease. In: Perry E, McKeith JG (eds) Dementia with Lewy bodies. Cambridge University Press, New York, pp 268–286.CrossRefGoogle Scholar
  68. Jellinger K, Braak H, Braak E, Fischer P (1991) Alzheimer lesions in the entorhinal region and isocortex in Parkinson’s and Alzheimer’s diseases. Ann NY Acad Sci 640:203–209.PubMedGoogle Scholar
  69. Jellinger KA, Bancher C, Fischer P (1993) Neuropathological correlates of mental dysfunction in Parkinson’s disease. In: Wolters ECh, Schelten S (eds) Mental dysfunction in Parkinson’s disease. Vrije Universiteit, Amsterdam, pp 141–161.Google Scholar
  70. Jones RSG (1993) Entorhinal-hippocampal connections: a speculative view of their function. Trends Neurosci 16: 58–64.PubMedCrossRefGoogle Scholar
  71. Kazee AM, Han LY (1995) Cortical Lewy bodies in Alzheimer’s disease. Arch Pathol Lab Med 119: 448–453.PubMedGoogle Scholar
  72. Khachaturian ZS (1985) Diagnosis of Alzheimer’s disease. Arch Neurol 42: 1097–1105.PubMedCrossRefGoogle Scholar
  73. Klingberg T, Roland PE, Kawashima (1994) The human entorhinal cortex participates in associative memory. Neuro Report 6: 57–60.Google Scholar
  74. Koller WC, Glatt SL, Hubble JP (1995) Apolipoprotein E genotypes in Parkinson’s disease with and without dementia. Ann Neurol 37: 242–245.PubMedCrossRefGoogle Scholar
  75. Kosaka K (1993) Dementia and neuropathology in Lewy body disease. Adv Neurol 60:456–463.PubMedGoogle Scholar
  76. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E (1993) Neurotransmitters in basal ganglia and cortex of Alzheimer’s disease with and without Lewy bodies. Neurology 43: 1927–1934.PubMedCrossRefGoogle Scholar
  77. Lassmann H, Weiler R, Fischer P, Bancher C, Jellinger K, et al. (1992) Synaptic pathology in Alzheimer’s disease: immunological data for markers of synaptic and large dense core vesicles. Neuroscience 46: 1–8.PubMedCrossRefGoogle Scholar
  78. Lassmann H, Fischer P, Jellinger K (1993) Synaptic pathology of Alzheimer’s disease. Ann NY Acad Sci 695: 59–64.PubMedCrossRefGoogle Scholar
  79. Lehericy S, Hirsch EC, Pervera-Plerot P, Javoy-Agid F, Agid Y (1993) Heterogeneity of the degeneration of cholinergic neurons in basal forebrain in patients with Alzheimer’s disease. J Comp Neurol 330: 15–31.PubMedCrossRefGoogle Scholar
  80. Lippa CF, Smith TW, Swearer JM (1994) Alzheimer’s disease and Lewy body disease: a comparative clinicopathological study. Ann Neurol 35: 81–88.PubMedCrossRefGoogle Scholar
  81. Lippa CF, Smith TW, Saunders AM, et al. (1995) Apolipoprotein E genotype and Lewy body disease. Neurology 45: 97–103.PubMedCrossRefGoogle Scholar
  82. Louis ED, Goldman JE, Powers JM, Fahn S (1995) Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord 10:188–194.PubMedCrossRefGoogle Scholar
  83. Love S, Wilcock GK, Matthews SM (1995) No correlation between nigral degeneration and striatal plaques in Alzheimer’s disease. Acta Neuropathol 91: 432–435.CrossRefGoogle Scholar
  84. Manaye KF, Woodward K, Mclntire DD, Mann DMA, German DC (1994) Locus coeruleus cell loss on lobar atrophy. Neurodegeneration 3: 205–210.Google Scholar
  85. Marder K, Leung D, Tang M, Bell K, Doonelef G, Cote L, Stern Y, Mayeux R (1991) Are demented patients with Parkinson’s disease accurately reflected in prevalence surveys? A survival analysis. Neurology 41: 1240–1243.PubMedCrossRefGoogle Scholar
  86. Marder K, Cote L, Tang M, Stern Y, Maestre G, Tycko B, Mayeux R (1994) The risk and predictive factors associated with dementia in Parkinson’s disease. In: Korczyn AD (ed) Dementia in Parkinson’s disease. Monduzzi Ed, Bologna, pp 51–54.Google Scholar
  87. Marie RM, Barre L, Rioux P, Allain P, Lechevalier B, Baron JC (1995) PET imaging of neocortical monoaminergic terminals in Parkinson’s disease. J Neural Transm [PD-Sect] 9: 55–71.CrossRefGoogle Scholar
  88. Masliah E (1995) Mechanisms of synaptic dysfunction in Alzheimer’s disease. Histol Histopathol 10: 505–519.Google Scholar
  89. Mayeux R, Denaro J, Hemenglido N, Marder K Tang MX, Cote LJ, Stern Y (1992) A population-based investigation of Parkinson’s disease with and without dementia. Arch Neurol 49: 492–497.PubMedCrossRefGoogle Scholar
  90. McKeith IG, Fairbairn AF, Bothwell RA, et al. (1994) An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of Lewy body type. Neurology 44: 872–877.PubMedCrossRefGoogle Scholar
  91. Mindham RHS, Biggins CA, Boyd JL, et al. (1993) A controlled study of dementia in Parkinson’s disease over 54 months. Adv Neurol 60: 469–474.Google Scholar
  92. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, Van Belle G, Berg L (1991) The Consortium to establish a registry for Alzheimer’s disease (CERAD). II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 41: 479–486.Google Scholar
  93. Morris CM, Massey HM, Benjamin R, et al. (1996) Molecular biology of APO E alleles in Alzheimer’s and non-Alzheimer’s dementias. J Neural Transm [Suppl] 47: 205–218.CrossRefGoogle Scholar
  94. Mufson EJ, Conner JM, Kordower JH (1995) Nerve growth factor in Alzheimer’s disease. Defective retrograde transport to nucleus basalis. Neuroreport 6: 1063–1066.Google Scholar
  95. Murray AM, Weihmueller FB, Marshall JF, Hurtig HI, Gottleib GL, Joyce JN (1995) Damage to dopamine systems differs between Parkinson’s disease and Alzheimer’s disease with parkinsonism. Ann Neurol 37: 300–312.PubMedCrossRefGoogle Scholar
  96. Nieuwenhuys R, Voogel J, Van Huizen C (1988) The human central nervous system. A synopsis and atlas, 3rd ed. Springer, Berlin Heidelberg New York Tokyo Google Scholar
  97. Parent A, Hazrati L-N (1995) Functional anatomy of the basal ganglia. I. The cortico-basal-ganglia-thalamo-corticol loop. Brain Res Rev 20: 91–127.PubMedCrossRefGoogle Scholar
  98. Paulus W, Jellinger K (1991) The neuropthologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 50: 743–755.PubMedCrossRefGoogle Scholar
  99. Pendlebury WW, Perl D (1984) Nucleus basalis of Meynert. Severe loss in Parkinson’s disease without dementia (Abstr). Ann Neurol 16: 129Google Scholar
  100. Peppard RF, Martin WRW, Carr GD, Grochoswski E, Schulzer M, et al. (1992) Cerebral glucose metabolism in Parkinson’s disease with and without dementia. Arch Neurol 49: 1262–1268.PubMedCrossRefGoogle Scholar
  101. Perry EK, Irving D, Kerwin JM, McKeith IG, Thompson P, Collerton D, Fairbairn AP, Ince PG, Morris CM, Cheng AV, Perry RM (1993) Cholinergic transmitter and neurotrophic activities in Lewy body dementia. Similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 7: 69–79.CrossRefGoogle Scholar
  102. Perry EK, Morris CM, Court JA, Choung A, Fairbairn AF, McKeith JG, Irving D, Brown A, Perry RH (1995) Alteration in nicotin binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience 64: 385–395.PubMedCrossRefGoogle Scholar
  103. Pillon B, Deweer B, Malapani C, Rogelet P, Agid Y, Dubois B (1994a) Explicit memory disorders of demented parkinsonian patients and underlying neuronal basis. In: Korczyn AD (ed) Dementia in Parkinson’s disease. Monduzzi Ed, Bologna, pp 265–271.Google Scholar
  104. Pillon B, Michon A, Malapani C, Agid Y, Dubois B (1994b) Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer’s, Parkinson’s and Huntington’s diseases. Neurology 44: 1264–1270.PubMedCrossRefGoogle Scholar
  105. Playford ED, Jenkins IH, Passingham RF, Nutt J, Frackowiak RSJ, Brooks DJ (1992) Impaired mesial frontal and putamen activation in Parkinson’s disease: a positron emission tomography study. Ann Neurol 32: 151–161.PubMedCrossRefGoogle Scholar
  106. Reid WJG, Broe, GA, Morris JGL (1992) The role of cholinergic deficiency in neuropsychological deficits in idiopathic Parkinson’s disease. Dementia 3: 114–120.Google Scholar
  107. Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frakowiak RSJ, Dolan RJ (1994) Depression in Parkinson’s disease. A positron emission study. Br J Psychiatry 165: 333–339.Google Scholar
  108. Rinne JO, Rummukainen J, Paljärvi J, Rinne UK (1989) Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 26: 47–50.PubMedCrossRefGoogle Scholar
  109. Rolls ET (1994) Neurophysiology and cognitive functions of the striatum. Rev Neurol 150: 648–660.PubMedGoogle Scholar
  110. Ruberg M, Agid Y (1988) Dementia in Parkinson’s disease. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 20. Psychopharmacology of aging nervous system. Plenum Press, New York, pp 157–206.CrossRefGoogle Scholar
  111. Samuel W, Masliah E, Hikll R, Butters N, Terry R (1994a) Hippocampal connectivity and Alzheimer’s dementia: effects of synapse loss and tangle frequency in a two-component model. Neurology 44: 2081–2088.PubMedCrossRefGoogle Scholar
  112. Samuel W, Terry RD, DeTeresa R, et al. (1994b) Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch Neurol 51: 772–778.PubMedCrossRefGoogle Scholar
  113. Samuel W, Galasko D, Masliah E, Hansen LA (1996) Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer’s disease. J Neuropathol Exp Neurol 55: 44–52.PubMedCrossRefGoogle Scholar
  114. Saper CD, German DC, White CL (1985) Neuronal pathology in the nucleus basalis of Meynert and associated cell groups in senile dementia of the Alzheimer’s type. Possible role of cell loss. Neurology 35: 1089–1095.Google Scholar
  115. Sawaguchi T, Goldman-Rakic PS (1991) Dl dopamine receptors in prefrontal cortex: involvement in working memory. Science 251: 247–250.CrossRefGoogle Scholar
  116. Scott SA, DeKosky ST, Sparks DL, Knox CA, Scheff SW (1992) Amygdala cell loss and atrophy in Alzheimer’s disease. Ann Neurol 32: 555–563.PubMedCrossRefGoogle Scholar
  117. Sims KS, Williams RS (1990) The human amygdaloid complex. Neuroscience 36: 449–472.PubMedCrossRefGoogle Scholar
  118. Smith MA, Perry G (1994) Is a Lewy body always a Lewy body? In: Korczyn AD (ed) Dementia in Parkinson’s disease. Monduzzi Ed, Bologna, pp 187–193.Google Scholar
  119. Steriade M, Biesold D (1990) Brain cholinergic systems. Oxford University PressGoogle Scholar
  120. Stern Y, Marder K, Tang MX, Mayeux R (1993) Antecedent clinical features associated with dementia in Parkinson’s disease. Neurology 43: 1690–1692.PubMedCrossRefGoogle Scholar
  121. Stern Y, Richards M, Sano M, Mayeux R (1993) Comparison of cognitive changes in patients with Alzheimer’s and Parkinson’s disease. Arch Neurol 50: 1040–1045.PubMedCrossRefGoogle Scholar
  122. Strong C, Anderton BH, Perry RH, et al. (1995) Abnormally phosphorylated tau protein in senile dementia of Lewy body type and Alzheimer disease; evidenced that the disorders are distinct. Alzheimer Dis Assoc Disord 9: 215–222.Google Scholar
  123. Tagliavini F, Pilleri G, Bouras C, Constantinidis J (1984) The basal nucleus of Meynert in idiopathic Parkinson’s disease. Acta Neurol Scand 69: 20–28.CrossRefGoogle Scholar
  124. Tatemichi TK, Sacktor N, Mayeux R (1994) Dementia associated with cerebrovascular disease, other degenerative diseases, and metabolic disorders. In: Terry RD, Katzman R, Bick KL (eds) Alzheimer disease. Raven Press, New York, pp 123–166.Google Scholar
  125. Terry RD, Masliah E, Salmon DP (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572–580.PubMedCrossRefGoogle Scholar
  126. Terry RD, Masliah E, Hansen LA (1994) Structural basis of the cognitive alterations in Alzheimer’s disease. In: Terry RD, Katzman R, Bick KL (eds) Alzheimer disease. Raven Press, New York, pp 179–196.Google Scholar
  127. Tison F, Dartigues JF, Auriacombe S, Letenneur L, Boller F, Alperovich A (1995) Dementia in Parkinson’s disease. A population-based study in ambulatory and institutionalized individuals. Neurology 45: 705–708.Google Scholar
  128. Troster AL, Paolo AM, Lyons KE, Glatt SL, Hubble JP, Koller WC (1995) The influence of depression on cognition in Parkinson’s disease. A pattern impairment distinguishable from Alzheimer’s disease. Neurology 45: 672–676.Google Scholar
  129. Uitti RJ, Berry K, Yasuhara O, et al. (1995) Neurodegenerative “overlap” syndrome: clinical and pathological features of Parkinson’s disease, motor neuron disease, and Alzheimer’s disease. Park Rel Dis 1: 21–34.CrossRefGoogle Scholar
  130. Vereecken ThHLG, Vogels OJM, Nieuwenhuys R (1994) Neuron loss and shrinkage in the amygdala in Alzheimer’s disease. Neurobiol Aging 15: 45–54.PubMedCrossRefGoogle Scholar
  131. Vermersch P, Frigard B, Delacourte A (1992) Mapping of neurofibrillary degeneration in Alzheimer’s disease; evaluation of heterogeneity using the quantification of abnormal tau proteins. Acta Neuropathol 85: 48–54.PubMedCrossRefGoogle Scholar
  132. Vermersch P, Delacourte A, Javoy-Agid F, Hauw JJ, Agid Y (1993) Dementia in Parkinson’s disease: biochemical evidence for cortical involvement using the immunodetection of abnormal tau proteins. Ann Neurol 33: 445–450.PubMedCrossRefGoogle Scholar
  133. Vermersch P, Robitaille Y, Bernier L, et al. (1994) Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: evidence for general cortical involvement. Acta Neuropathol 87: 572–577.PubMedCrossRefGoogle Scholar
  134. Xuereb JH, Tomlinson BE, Irfing D, et al. (1990) Cortical and subcortical pathology in Parkinson’s disease: relationship to parkinsonian dementia. Adv Neurol 53: 35–40.PubMedGoogle Scholar
  135. Zubenko GS (1992) Biological correlates of clinical heterogeneity in primary dementia. Neuropsychopharmacology 6: 72–93.Google Scholar
  136. Zweig RM, Cardilio JE, Cohen M, Giere S, Hedreen JC (1993) The locus ceruleus and dementia in Parkinson’s disease. Neurology 43: 986–991.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • K. A. Jellinger
    • 1
  1. 1.Ludwig Boltzmann Institute of Clinical NeurobiologyViennaAustria

Personalised recommendations